Nina Houben

Ms. Nina Houben

Division of Neonatology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Nina HoubenNina Houben
Nina Houben
LHLisanne E. Heeger
Lisanne E. Heeger
SSSimon J. Stanworth
Simon J. Stanworth
HNHelen V. New
Helen V. New
JBJohanna (Anske) Gerarda van der Bom
Johanna (Anske) Gerarda van der Bom
Enrico LoprioreEnrico Lopriore
Enrico Lopriore
The aim of this study was to evaluate changes in the use of fresh-frozen plasma (FFP) transfusions and the use of clotting tests in preterm neonates in our center over the past two decades. In this retrospective cohort analysis, we included all consecutive neonates with a gestational age at birth between 24 + 0 and 31 + 6 weeks admitted to our neonatal intensive care unit (NICU) between 2004 and 2019. We divided all included neonates into three consecutive time epochs according to date of birth: January 2004 to April 2009, May 2009 to August 2014 and September 2014 to December 2019. The main outcomes were the use of FFP transfusion, coagulation testing and the indications for FFP transfusion. The percentage of preterm neonates receiving FFP transfusion decreased from 5.7% (47/824) to 3.7% (30/901) to 2.0% (17/852) from the first epoch to the last epoch (p < 0.001). Additionally, the rate of neonates undergoing coagulation testing decreased from 24.3% (200/824) to 14.5% (131/901) to 8% (68/852) over the epochs (p < 0.001). Most FFP transfusions were prescribed prophylactically based on prolongation of activated partial thromboplastin time (aPTT) or prothrombin time (PT) (56%). In conclusion, both the use of FFP transfusions and the use of coagulation tests decreased significantly over the years. The majority of the FFP transfusions were administrated prophylactically for abnormal coagulation tests.

19 January 2025 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Open access
PDF file
Nina HoubenNina Houben
Nina Houben
SFSuzanne Fustolo-Gunnink
Suzanne Fustolo-Gunnink
KFKarin Fijnvandraat
Karin Fijnvandraat
CCCamila Caram-Deelder
Camila Caram-Deelder
MCMarta Aguar Carrascosa
Marta Aguar Carrascosa
Enrico LoprioreEnrico Lopriore
Enrico Lopriore
Objective Despite lack of evidence supporting efficacy, prophylactic fresh frozen plasma and Octaplas transfusions may be administered to very preterm infants to reduce bleeding risk. International variation in plasma transfusion practices in neonatal intensive care units (NICUs) is poorly understood, therefore, we aimed to describe neonatal plasma transfusion practice in Europe. Design Prospective observational study. Setting 64 NICUs in 22 European countries, with a 6-week study period per centre between September 2022 and August 2023. Patients Preterm infants born below 32 weeks of gestational age. Interventions Admission to the NICU. Main outcome measures Plasma transfusion prevalence, cumulative incidence, indications, transfusion volumes and infusion rates and adverse effects. Results A total of 92 of 1143 infants included (8.0%) received plasma during the study period, collectively receiving 177 transfusions. Overall prevalence was 0.3 plasma transfusion days per 100 admission days, and rates varied substantially across Europe. By day 28 of life, 13.5% (95% CI 10.0% to 16.9%) of infants received at least one plasma transfusion, accounted for competing risks of death or discharge. Transfusions were given for a broad range of indications, including active bleeding (29.4%), abnormal coagulation screen results (23.7%) and volume replacement/hypotension (21.5%). Transfusion volumes and infusion rates varied significantly; the most common volume was 15 mL/kg (range: 5–30 mL/kg) and the most common duration was 2 hours (range: 30 min to 6 hours). Conclusions We found wide variation in plasma transfusion practices in Europe, highlighting the need for evidence to inform neonatologists in daily practice and guidelines, in particular for non-bleeding indications. Trial registration number ISRCTN17267090.

11 October 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
Nina HoubenNina Houben
Nina Houben
ELEnrico Lopriore
Enrico Lopriore
KFKarin Fijnvandraat
Karin Fijnvandraat
CCCamila Caram-Deelder
Camila Caram-Deelder
MCMarta Aguar Carrascosa
Marta Aguar Carrascosa
IGINSPIRE Study Group
INSPIRE Study Group
Platelet transfusions are given to preterm infants with severe thrombocytopenia aiming to prevent haemorrhage. The PlaNeT2/MATISSE trial revealed higher rates of mortality and/or major bleeding in preterm infants receiving prophylactic platelet transfusions at a platelet count threshold of 50 × 109/L compared to 25 × 109/L. The extent to which this evidence has been incorporated into clinical practice is unknown, thus we aimed to describe current neonatal platelet transfusion practices in Europe. We performed a prospective observational study in 64 neonatal intensive care units across 22 European countries between September 2022 and August 2023. Outcome measures included observed transfusion prevalence rates (per country and overall, pooled using a random effects Poisson model), expected rates based on patient-mix (per country, estimated using logistic regression), cumulative incidence of receiving a transfusion by day 28 (with death and discharge considered as competing events), transfusion indications, volumes and infusion rates, platelet count triggers and increment, and adverse effects. We included 1143 preterm infants, of whom 71 (6.2%, [71/1143]) collectively received 217 transfusions. Overall observed prevalence rate was 0.3 platelet transfusion days per 100 admission days. By day 28, 8.3% (95% CI: 5.5-11.1) of infants received a transfusion. Most transfusions were indicated for threshold (74.2%, [161/217]). Pre-transfusion platelet counts were above 25 × 109/L in 33.1% [53/160] of these transfusions. There was significant variability in volume and duration. The restrictive threshold of 25 × 109/L is being integrated into clinical practice. Research is needed to explore existing variation and generate evidence for various aspects including optimal volumes and infusion rates. Sanquin, EBA, and ESPR.

5 June 2025 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Closed access
PDF file
LVLianne Verbeek
Lianne Verbeek
VCValeria Cortesi
Valeria Cortesi
JDJip van Daelen
Jip van Daelen
TKThomas Klei
Thomas Klei
Nina HoubenNina Houben
Nina Houben
Enrico LoprioreEnrico Lopriore
Enrico Lopriore
Objectives: To determine the percentage of adequate umbilical cord blood (UCB) collections defined as ≥70 mL of UCB after delayed cord clamping for 3 min was applied. Second, to correlate the UCB volume to gestational age at birth, birth weight and sex. Design: We conducted a multicentre, prospective, feasibility study in near-term infants delivered through caesarean section between November 2023 and December 2024. UCB was collected ex-utero, immediately after the placenta was removed from the womb. Results: A total of 195 UCB collections were attempted. In 11 cases (5.6%), the attempt failed due to rupture of the umbilical cord or damaged placenta by removal of the placenta from the uterus. The median volume of the remaining 184 UCB collections was 72 mL (IQR 56–86 mL). In only 54% (100/184), the UCB volume reached the target volume of ≥70 mL. We found that UCB volume was positively associated with birth weight (R 2 =0.0813, F(1181)=16.02, p value <0.001) but not with gestational age at birth (R 2 =0.0014, F(1181)=0.2553, p value=0.614). Conclusions: A sufficient UCB volume (≥70 mL) was obtained in approximately half of the attempts. A higher birth weight was associated with a larger volume of UCB collection.

30 September 2025 in Transfusion
Verified
Journal Article
Open access
Nina HoubenNina Houben
Nina Houben
CCCamila Caram‐Deelder
Camila Caram‐Deelder
ELEnrico Lopriore
Enrico Lopriore
SFSuzanne Fustolo‐Gunnink
Suzanne Fustolo‐Gunnink
TCThe Inspire Contributors
The Inspire Contributors
Many preterm infants are exposed to multiple transfusion types during their admission in the neonatal intensive care unit. Yet, evidence supporting current practice consists of several randomized controlled trials and observational studies focusing on a single transfusion product at the time. Rather than approaching transfusions as three distinct categories as currently done in the literature, there may be benefit by accounting for the interconnected nature of these practices. In this Clinical Research Focus article, we advocate for a broader perspective in future research on neonatal transfusion practices. By looking at the whole instead of its parts, we can gain a more comprehensive understanding of the impact of transfusion exposure, potential associated adverse effects, and their implications for neonatal care.